Want to see AU:CLV full AI Analyst Report?
CLV Stock Chart & Stats
AU$0.91
AU$0.06(6.25%)
At close: 4:00 PM EDT
AU$0.91
AU$0.06(6.25%)
Day’s Range― - ―
52-Week RangeAU$0.62 - AU$1.17
Previous CloseN/A
Volume74.89K
Average Volume (3M)240.03K
Market Cap
AU$175.35M
Enterprise ValueAU$154.17M
Total Cash (Recent Filing)AU$7.22M
Total Debt (Recent Filing)AU$1.07M
Price to Earnings (P/E)15.9
Beta0.15
Next Earnings
Mar 16, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.36%
Share Statistics
EPS (TTM)0.06
Shares Outstanding166,999,340
10 Day Avg. Volume276,437
30 Day Avg. Volume240,028
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.06
Price to Sales (P/S)1.65
P/FCF Ratio48.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$115.05M
Bulls Say, Bears Say
Bulls Say
Profitable Revenue Growth And Margin ExpansionStrong revenue growth combined with higher gross margins and substantial EBITDA and NPAT gains indicates meaningful operating leverage. If product mix, innovation and vertical integration continue supporting profitability, Clover can strengthen earnings capacity over the next several reporting periods.
Conservative Balance Sheet And Debt EliminationThe debt-free balance sheet and cash holdings provide financial resilience and reduce exposure to interest costs or refinancing pressure. This gives Clover greater flexibility to fund product development, market expansion and capacity investment while preserving the ability to withstand operating volatility.
Diversified Product Portfolio And Expanding ARA DemandBroader product contribution and strong global ARA adoption can reduce reliance on Clover’s traditional base products and create a more durable revenue mix. Broad customer qualification, longer-term contracted sales and growth across regions support continued commercial relevance.
Bears Say
Working-capital Intensity Weakens Cash ConversionHigher inventory and working-capital requirements are absorbing cash even as reported earnings improve. The need to purchase, test, process and hold more oil and finished goods may keep cash conversion volatile, limiting internally funded investment and reducing the quality of near-term earnings.
CholineXcel Capacity Limits CommercializationManufacturing capacity is a direct constraint on CholineXcel’s ability to convert successful trials and customer interest into material revenue. Delayed scale-up could defer the product’s contribution, extend development spending and limit Clover’s ability to serve larger infant-formula opportunities.
U.S. Market Entry Remains Difficult And CostlyThe difficult U.S. track record indicates that expanding into a large nutraceutical market may require sustained execution and investment before producing meaningful returns. Continued market-development costs over the next two to three years could pressure margins if customer access and sales growth remain limited.
Clover Corporation Limited News
CLV FAQ
What was Clover Corporation Limited’s price range in the past 12 months?
Clover Corporation Limited lowest share price was AU$0.62 and its highest was AU$1.17 in the past 12 months.
What is Clover Corporation Limited’s market cap?
Clover Corporation Limited’s market cap is AU$175.35M.
When is Clover Corporation Limited’s upcoming earnings report date?
Clover Corporation Limited’s upcoming earnings report date is Mar 16, 2027 which is in 144 days.
How were Clover Corporation Limited’s earnings last quarter?
Clover Corporation Limited released its earnings results on Sep 22, 2026. The company reported AU$0.037 earnings per share for the quarter.
Is Clover Corporation Limited overvalued?
According to Wall Street analysts Clover Corporation Limited’s price is currently Overvalued.
Does Clover Corporation Limited pay dividends?
Clover Corporation Limited pays a Semiannually dividend of AU$0.013 which represents an annual dividend yield of 2.36%. See more information on Clover Corporation Limited dividends here
What is Clover Corporation Limited’s EPS estimate?
Clover Corporation Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Corporation Limited have?
Clover Corporation Limited has 166,999,340 shares outstanding.
What happened to Clover Corporation Limited’s price movement after its last earnings report?
Clover Corporation Limited reported an EPS of AU$0.037 in its last earnings report. Following the earnings report the stock price went down -3.731%.
Which hedge fund is a major shareholder of Clover Corporation Limited?
Currently, no hedge funds are holding shares in AU:CLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Corporation Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CLV Sentiment 100%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth AU$119.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.75%
12-Months-Change
Fundamentals
Return on Equity
13.83%
Trailing 12-Months
Asset Growth
12.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Clover Corporation Limited
Clover Corporation Limited engages in the processing and worldwide sale of natural oils, reaching markets across Australia, New Zealand, Asia, Europe, and the Americas. The company's operations also encompass the creation of encapsulated products and extensive research and development focused on functional food and infant nutrition ingredients. Among its principal offerings are Nu-Mega Hi docosahexaenoic tuna oils, designed for use in infant formula and pharmaceutical goods, alongside its Ocean Gold refined tuna oils. Furthermore, it supplies Nu-Mega Driphorm powders, which are incorporated into various infant formulas, follow-on formulas, growing-up milks, and general food products, as well as Nu-Mega Driphorm HA for non-dairy applications. These products cater to several segments, including active living (for immune and sports support), healthy living (benefiting brain and heart health), and the foundational stages of infant and child development. The company, founded in 1988, maintains its corporate headquarters in Altona North, Australia.
Technical Analysis
Noumi Limited
―
Bega Cheese Limited
―
Bioxyne Limited
―
Bubs Australia Ltd.
―
Nutritional Growth Solutions Ltd.
―